Prot #PCYC-1112-CA: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date3/26/13 → 11/30/14

Funding

  • Pharmacyclics, Inc. (Prot #PCYC-1112-CA)